Últimas noticias sobre Corvus Pharma (NASDAQ:CRVS) Bolsa

Corvus Pharma

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42550503/corvus-pharmaceuticals-announces-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-so" rel="noreferrer noopener">severe atopic dermatitis</a>.&nbsp;
The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy.
These doses were selected based on the company&#8217;s prior experience evaluating soquelitinib in T-cell lymphoma patients.
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.
The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients.
EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo.
The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group.
<ul>
<li>At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of the 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and none achieved EASI 75, EASI 90, or IGA 0 or 1.</li>
<li>At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50, and no patients achieved EASI 75, EASI 90, or IGA 0 or 1.</li>
</ul>
No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery.
Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42556198/united-microelectronics-signs-landmark-renewable-energy-deal-with-fengmiao-i-offshore-wind-farm-stock-gains" target="_blank" rel="noreferrer noopener">United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains</a></li>
</ul>

Biotech

Health Care

Movers

General

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Wednesday.
The Dow traded up 0.52% to 43,674.00 while the NASDAQ rose 0.26% to 20,161.35. The S&amp;P 500 also rose, gaining, 0.31% to 6,069.24.
Check This Out: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares rose by 0.6% on Wednesday.
In trading on Wednesday, real estate shares fell by 0.3%.
Top Headline
General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) shares fell around 3% on Wednesday following the release of second-quarter results.
The company reported second-quarter adjusted earnings per share of $1.40, beating the street view of $1.22. Quarterly sales of $5.24 billion beat the analyst consensus estimate of $5.14 billion.
General Mills has revised its FY25 adjusted EPS outlook, now expecting a decline of 3% to 1% in constant currency. This adjustment compares to the previous outlook range of a decline of 1% to a growth of 1% in constant currency.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares shot up 227% to $3.4277 after the company announced it secured a GMP partnership with Eurofins CDO Amatsiaquitaine.</li>
<li>Shares of KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>)got a boost, surging 200% to $0.5353 after the company announced it regained NYSE stockholders&#8217; equity required compliance status.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) shares were also up, gaining 16% to $44.35 as the company posted better-than-expected results for its second quarter.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares dropped 41% to $3.7280. TransCode Therapeutics announced Safety Review Committee approval of opening third cohort and preliminary results from first cohort in Phase 1 TTX-MC138 clinical trial.</li>
<li>Shares of HEICO Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) were down 9% to $236.77 following mixed fourth-quarter results.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) was down, falling 46% to $4.02. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $71.02 while gold traded down 0.4% at $2,651.90.
Silver traded down 1% to $30.625 on Wednesday, while copper rose 0.2% to $4.1535.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.15%, Germany's DAX fell 0.02% and France's CAC 40 rose 0.26%. Spain's IBEX 35 Index gained 0.26%, while London's FTSE 100 rose 0.05%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.72%, Hong Kong's Hang Seng Index gaining 0.83%, China's Shanghai Composite Index gaining 0.62% and India's BSE Sensex falling 0.62%.
Economics
<ul>
<li>U.S. mortgage applications fell by 0.7% from the previous week during the week ending Dec. 13, compared to the 5.4% gain in the previous week.</li>
<li>The U.S. recorded a current account deficit of $310.9 billion in the third quarter compared to the revised gap of $275.0 billion in the previous period and versus market estimates of a $284 billion gap.</li>
<li>U.S. housing starts fell 1.8% to an annualized rate of 1.289 million units in November from 1.312 million in October.</li>
<li>U.S. building permits in gained by 6.1% to an annualized rate of 1.505 million in November.</li>
<li>U.S. stocks of crude oil declined by 934 thousand barrels in the second week of December, compared to a 1.425 million barrel fall in the previous week, and versus market expectations of a 1.7 million barrel decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42554270/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

KULR

PLRZ

RNAZ

Crude Oil Gains Over 1%, General Mills Shares Fall

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 150 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.36% to 43,607.95 while the NASDAQ rose 0.07% to 20,123.16. The S&amp;P 500 also rose, gaining, 0.12% to 6,058.13.
Check This Out: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares rose by 0.5% on Wednesday.
In trading on Wednesday, energy shares fell by 0.5%.
Top Headline
The U.S. recorded a current account deficit of $310.9 billion in the third quarter compared to the revised gap of $275.0 billion in the previous period and versus market estimates of a $284 billion gap.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares shot up 273% to $3.9199 after the company announced it secured a GMP partnership with Eurofins CDO Amatsiaquitaine.</li>
<li>Shares of Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) got a boost, surging 200% to $0.5353.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares were also up, gaining 214% to $1.32.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares dropped 49% to $3.24. TransCode Therapeutics announced Safety Review Committee approval of opening third cohort and preliminary results from first cohort in Phase 1 TTX-MC138 clinical trial.</li>
<li>Shares of XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) were down 48% to $12.21.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) was down, falling 46% to $4.0098. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.</li>
</ul>
Commodities In commodity news, oil traded up 1.2% to $70.93 while gold traded down 0.3% at $2,653.10.
Silver traded down 0.7% to $30.700 on Wednesday, while copper rose 0.3% to $4.1580.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX rose 0.2% and France's CAC 40 rose 0.4%. Spain's IBEX 35 Index gained 0.6%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.72%, Hong Kong's Hang Seng Index gaining 0.83%, China's Shanghai Composite Index gaining 0.62% and India's BSE Sensex falling 0.62%.
Economics
<ul>
<li>U.S. mortgage applications fell by 0.7% from the previous week during the week ending Dec. 13, compared to the 5.4% gain in the previous week.</li>
<li>The U.S. recorded a current account deficit of $310.9 billion in the third quarter compared to the revised gap of $275.0 billion in the previous period and versus market estimates of a $284 billion gap.</li>
<li>U.S. housing starts fell 1.8% to an annualized rate of 1.289 million units in November from 1.312 million in October.</li>
<li>U.S. building permits in gained by 6.1% to an annualized rate of 1.505 million in November.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42554270/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

LITM

NVNI

Dow Surges 150 Points, US Current Account Deficit Widens In Q3

U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday.
Shares of HEICO Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/HEI/earnings">fourth-quarter results</a>.
Heico reported quarterly earnings of 99 cents per share which beat the analyst consensus estimate of 98 cents per share. The company reported quarterly sales of $1.01 billion which missed the analyst consensus estimate of $1.03 billion.
HEICO shares dipped 5.7% to $245.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares dipped 35.7% to $4.74 in pre-market trading. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) shares declined 25.2% to $28.72 in pre-market trading after jumping 28% on Tuesday.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) declined 22.2% to $3.51 in pre-market trading.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) fell 9.6% to $32.00 in pre-market trading.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares dipped 8.6% to $36.00 in pre-market trading ahead of quarterly earnings.</li>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) shares fell 6.3% to $29.50 in pre-market trading. Structure Therapeutics announced selection of lead oral small molecule amylin receptor agonist ACCG-2671 for the treatment of obesity.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 2.1% to $469.95 in pre-market trading. Baird analyst Ben Kallo maintained Tesla with an Outperform and raised the price target from $280 to $480.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Top 3 Health Care Stocks That May Explode In Q4</a></li>
</ul>

Pre-Market Outlook

FTEL

GPCR

RADX

TSLA

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

WIIM

Corvus Pharmaceuticals shares are trading lower. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

Corvus Pharmaceuticals Announced Interim Data From The Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Trial Evaluating Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis

PLRZ: 282% &#x7C; <a href="https://www.benzinga.com//node/42549301">Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025</a>
&nbsp;
CRVS: 24% &#x7C; <a href="https://www.benzinga.com//node/42540476">Corvus Pharmaceuticals shares are trading higher after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.</a>
&nbsp;
OKLO: 10% &#x7C; <a href="https://www.benzinga.com//node/42550029">Oklo And Switch Partner To Deploy 12 GW Of Advanced Nuclear Power</a>

OKLO

Market-Moving News for December 18th

U.S. stock futures climbed on Wednesday in premarket hours as Wall Street awaits the Federal Reserve&#8217;s final interest rate decision for 2024 and its monetary policy forecasts for 2025.
On Tuesday, the Dow Jones index fell for the <a href="https://www.benzinga.com/news/earnings/24/12/42546507/dow-records-longest-losing-streak-since-1978-nvidia-declines-fear-greed-index-in-neutral-zone">ninth session in a row</a> to record its longest losing streak since 1978.
The 10-year and two-year Treasury notes yielded 4.40% and 4.25%, respectively. The Federal Open Market Committee will announce its decision later in the day after a two-day meeting.
It is widely expected to announce another interest rate reduction at the conclusion of their meeting on Wednesday. Expectations of a 25 basis point rate cut rose to 95.4%, from 58.7% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
If the Fed cuts rates, it would be the third consecutive cut, bringing the federal funds rate down from its current level of 4.50% to 4.75%. Following the meeting, Chairman Jerome Powell&#8217;s remarks will be closely scrutinized by market participants.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
Prior to that, GDP revisions on Thursday will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.28%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.49%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.25% to $605.80 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.24% to $537.09, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The <a href="https://www.benzinga.com/news/earnings/24/12/42546507/dow-records-longest-losing-streak-since-1978-nvidia-declines-fear-greed-index-in-neutral-zone">Dow Jones Industrial Average </a>extended its losing streak to nine consecutive sessions on Tuesday, its longest downturn since 1978. This negative trend weighed on the broader U.S. stock market.
While Tesla shares rallied after a positive analyst upgrade, Nvidia experienced a slight decline.
On the economic front, U.S. retail sales exceeded expectations in November, suggesting increased consumer spending. However, industrial production contracted, signaling a slowdown in manufacturing activity.
The S&amp;P 500 saw a broad-based decline, with industrials, energy, and financials leading the losses. Consumer discretionary stocks, on the other hand, bucked the trend and closed higher.
At the close of trading, the Dow Jones Industrial Average had fallen by approximately 268 points to 43,449.90. The S&amp;P 500 and Nasdaq Composite also ended the day lower, declining by 0.39% and 0.32%, respectively.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.32%</td>
<td>20,109.06</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.39%</td>
<td>6,050.61</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.61%</td>
<td>43,449.90</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.18%</td>
<td>2,334.08</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The Dow Jones Industrial Average index last saw a nine-day fall for the first time since February 1978, according to FactSet data. However, the index has seen steeper crashes in a single day as compared to the cumulative erosion it has witnessed over these nine days.
Dow Jones has fallen nearly 3.47% to 43,449.90 points over the last nine days since Dec. 4, when it was at 45,014.04 points.
&#8220;Since 1900, I see 267 times it lost more than 3.47% in a single day,&#8221; said Ryan Detrick, chief market strategist at Carson Research.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Dow is down 3.47% the past 9 days (and lower all 9 of them). Since 1900, I see 267 times it lost more than 3.47% in a single day.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1869205905780388184?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to BlackRock, the global economy is undergoing a transformation that could keep shifting the long-term economic trend. They suggest that investors should shift to distinct drivers of risk and return.
&#8220;That creates a wide range of potential outcomes and a need to use scenarios to guide portfolio construction, we think. Government bonds have become a less reliable cushion against risk asset selloffs in this new regime. So investors should consider new diversifiers like gold and bitcoin – not to replace bonds, but to get exposure to distinct drivers of risk and return.&#8221;
&#8220;We see the AI buildout and adoption creating opportunities across sectors,&#8221; BlackRock&#8217;s note added.
&#8220;Overall, with so much uncertainty around tariffs and inflation, bond market volatility is unlikely to fade anytime soon,&#8221; said JPMorgan in their note.
&#8220;The week's economic data releases appeared to be enough for markets to solidify expectations for a rate cut at the upcoming Federal Reserve meeting,&#8221; said T Rowe Price in their weekly note.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released this week that will help investors determine the future course of action.
<ul>
<li>On Wednesday, housing starts, and building permit data for November will be announced at 8:30 a.m., ET.</li>
<li>The FOMC&#8217;s interest rate decision will be announced at 2:00 p.m., ET, and the Fed Chair Jerome Powell&#8217;s press conference will begin at 2:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Parazero Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) was up 71.24% in premarket trading after it regained Nasdaq compliance.</li>
<li>Nukkleus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 45.37% after the company announced it acquired a 51% controlling stake in Star 26 Capital.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose 17.73% in premarket after it said that it would report interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis, on Dec. 18.</li>
<li>Applied DNA Sciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 13.04% in pre-market trading after reporting weak quarterly sales.</li>
<li>Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) was up 13.28% after it received a NASA contract doe Goddard Space Flight Center to use its entropy quantum optimization machine to help the space agency&#8217;s imaging.</li>
<li>Investors are awaiting earnings results from General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>), Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>, )) and Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.03% to hover around $70.08 per barrel.
The gold spot index rose by 0.08% to $2,664.21 per ounce. The dollar index was up 0.04% to 106.997 level.
Asian markets were mixed on Wednesday, as Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, and South Korea&#8217;s Kospi index advanced. Whereas, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and Australia&#8217;s ASX 200 index declined. Most European markets advanced.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42548385/fund-managers-increase-allocation-to-banking-and-insurance-stocks-in-december-here-are-the-best-performing-financial-stocks-in-2024">Fund Managers Increase Allocation To Banking And Insurance Stocks In December: Here Are The Best Performing Financial Stocks In 2024</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Previews

Economics

Federal Reserve

QUBT

US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose sharply in today's pre-market trading after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to<a href="https://www.benzinga.com/quote/CRVS"> severe atopic dermatitis</a>.
Corvus Pharmaceuticals shares jumped 22.5% to $9.06 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) gained 88.8% to $2.89 in pre-market trading after gaining 5% on Tuesday. ParaZero Technologies regained Nasdaq compliance.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) climbed 68.4% to $2.19 in pre-market trading after declining over 6% on Tuesday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company announced it has acquired a 51% controlling stake in Star 26 Capital.</li>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) gained 46% to $0.3278 in pre-market trading.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) rose 33% to $0.4417 in pre-market trading after dipping 37% on Tuesday.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 30.1% to $4.28 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 27.7% to $0.0780 in pre-market trading after jumping 20% on Tuesday.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) gained 26% to $1.55 in pre-market trading after jumping over 26% on Tuesday.</li>
<li>CommScope Holding Company, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 9.1% to $6.12 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares tumbled 29.9% to $0.30 in pre-market trading after jumping 56% on Tuesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) declined 24% to $0.38 in pre-market trading after jumping 87% on Tuesday.</li>
<li>KWESST Micro Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) shares fell 15.5% to $0.71 in pre-market trading after surging over 15% on Tuesday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 14.7% to $0.1962 in pre-market trading after reporting weak quarterly sales.</li>
<li>authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) dipped 13.8% to $5.00 in pre-market trading following a 4% decline in the previous session.</li>
<li>FS Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBW#NASDAQ">FSBW</a>) fell 13.4% to $39.01 in pre-market trading.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 12.5% to $7.90 in today's pre-market trading after jumping 182% on Tuesday.</li>
<li>SHL Telemedicine Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) fell 10% to $3.15 in pre-market trading following a 20% surge on Tuesday.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) fell 9.6% to $32.00 in pre-market trading.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares dipped 8.6% to $36.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Corvus Pharmaceuticals shares are trading higher after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.

Corvus Plans To Announce Interim Data From Phase 1 Clinical Trial Evaluating Soquelitinib In Patients With Moderate To Severe Atopic Dermatitis On December 18, 2024

Corvus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quality research relevant to all aspects of&nbsp;drug design and discovery.
The publication, entitled "Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity," includes a detailed overview of soquelitinib's mechanism of action – suppressing Th2 and Th17 cytokine production and sparing Th1 cytokines – that serves as a novel approach to cancer immunotherapy, both as a single agent and in combination with immune checkpoint inhibitors. The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function.

Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity

Corvus Pharmaceuticals shares are trading higher. The company reported Q3 financial results.

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Outperform and raises the price target from $8 to $14.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $14

Earnings Misses

Corvus Pharma Q3 2024 GAAP EPS $(0.60) Misses $(0.11) Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Corvus Pharma will report an earnings per share (EPS) of $-0.10. 
The announcement from Corvus Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.05, leading to a 9.67% increase in the share price the following trading session.
Here's a look at Corvus Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.12</td>
<td>-0.14</td>
<td>-0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-12.0%</td>
<td>-6.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333685_0.png" alt="eps graph" />
<h3>Corvus Pharma Share Price Analysis</h3>
Shares of Corvus Pharma were trading at $9.45 as of November 08. Over the last 52-week period, shares are up 538.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRVS/earnings">To track all earnings releases for Corvus Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Corvus Pharma's Earnings

The researchers created a murine model that confirmed that SPP1+ macrophages were associated with suppressed immunity to prostate cancer and shortened overall survival. Further analysis of the related genetic pathways revealed involvement of adenosine signaling through the adenosine 2A receptor. The researchers utilized ciforadenant to inhibit adenosine signaling in this model and the key findings demonstrating its potential to overcome this resistance to immunotherapy include:
<ul>
<li>Ciforadenant treatment associated with reduced immunosuppression and enhanced sensitivity to anti-PD1 therapy in the model&nbsp;</li>
<li>Ciforadenant treatment associated with reduced SPP1+ macrophage infiltration in the tumors, supporting a shift to a less immunosuppressive myeloid environment</li>
<li>The Adenosine Gene Signature, a biomarker that reflects adenosine induced immunosuppression in the tumor, was elevated in SPP1+ macrophages</li>
<li>Results from the model were consistent with data from the Phase 1b/2 clinical trial of ciforadenant in patients with mCRPC, which included data from 35 patients with advanced mCRPC, including 11 who received ciforadenant as a monotherapy (100 mg twice daily) and 24 that received ciforadenant (100 mg twice daily) in combination with atezolizumab (840 mg delivered intravenously every two weeks).&nbsp;5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions &gt;30%, compared to 1 of 11 (9%) receiving monotherapy</li>
</ul>

Reported Saturday, Corvus Pharmaceuticals Presents New Data Showing Ciforadenant's Potential To Overcome Immunotherapy Resistance In Advanced Prostate Cancer

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Monday.
Shares of Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/STLA/news">updated its 2024 guidance.</a>
Stellantis said it now expects FY24 operating margin of 5.5%-7.0%, down from its prior double-digit growth expectations.
Stellantis shares dipped 11.6% to $14.20 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares dipped 13% to $7.34 in pre-market trading after gaining over 5% on Friday.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) declined 11.6% to $4.55 in today's pre-market trading.</li>
<li>Venus Concept Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined 10.4% to $0.62 in pre-market trading. Venus Concept shares jumped around 20% on Friday after the company announced a $15 million debt-to-equity exchange transaction.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares fell 8.3% to $7.51 in pre-market trading.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) shares fell 6.1% to $3.86 in pre-market trading. Northland Capital Markets, last week, initiated coverage on the stock with an Outperform rating and announced a $6 price target.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares declined 6.1% to $165.51 in pre-market trading amid a decline in Bitcoin prices.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares fell 5.2% to $12.40 in pre-market trading amid a decline in Bitcoin prices.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares slipped 5.2% to $3.45 in pre-market trading amid a decline in Bitcoin prices.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>

APLD

BTBT

BTDR

CIFR

MSTR

STLA

VERO

Stellantis, MicroStrategy, Bit Digital And Other Big Stocks Moving Lower In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock moved upwards by 24.3% to $4.3 during Monday's pre-market session. The market value of their outstanding shares is at $516.1 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 16.2% to $6.67. The company's market cap stands at $20.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares increased by 14.28% to $2.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 13.81% to $10.3. The market value of their outstanding shares is at $11.0 million. As per the news, the Q2 earnings report came out today. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock increased by 13.01% to $9.12. The company's market cap stands at $152.1 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares rose 9.82% to $35.0. The market value of their outstanding shares is at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 20.8% to $0.23 during Monday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares declined by 11.66% to $4.55. The company's market cap stands at $284.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 11.28% to $0.55. The company's market cap stands at $2.4 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $38.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 10.13% to $0.57. The company's market cap stands at $7.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 7.5% to $0.66. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

ANAB

BNOX

ENSC

ESLA

PRME

PTIX

THAR

TRAW

12 Health Care Stocks Moving In Monday's Pre-Market Session

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRVS stock, giving a Buy rating yesterday. Graig Suvannavejh's r...

Corvus Pharmaceuticals' Soquelitinib: Optimism and Market Potential Drive Buy Rating

Corvus Pharmaceuticals (CRVS) announced new preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, ...

Corvus Pharmaceuticals announces preclinical dataon soquelitinib

Corvus Pharmaceuticals (CRVS) announced the publication of preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhi...

Corvus publishes data on potential of soquelitinib to modulate tumor activity

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Worthington Enterprises&nbsp;(WOR)&nbsp;u...

Closing Bell Movers: Heico slips 7% after Q4 results

Biggest stock movers Wednesday: COMM, HEI, and more

Corvus Pharmaceuticals (CRVS) announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquel...

Corvus Pharmaceuticals announce interim data from Phase 1 trial of soquelitinib

Corvus Pharmaceuticals ( ($CRVS) ) has issued an update. Corvus Pharmaceuticals announced promising interim data from their Phase 1 clinical trial ...

Comments

Corvus Pharma

Noticias

Últimas noticias sobre Corvus Pharma (NASDAQ:CRVS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL